Based on the current understanding of tumor heterogeneity and complex cellular signaling within the tumor and microenvironment and advances in molecular sequencing, we have identified both EGFR-dependent activating mutations and EGFR-independent mechanisms of resistance25–27. Here, EGFR is linked to neoplasm.